EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — HETERO LABS LTD V, approved 2022-01-24 (ANDA203053).
150,612 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.